Europe’s Drug Agency Warns on Work Crunch After Brexit Move
(Bloomberg) --
Europe's drug regulator warned that it will struggle to finish planned work for the year after its Brexit-spurred move out of the U.K., but said the main mission of approving new medicines won't be affected.
The European Medicines Agency has lost an additional 6% of staff since June, bringing its head count in Amsterdam down to 730, according to a statement following a Thursday board meeting. The oversight body had about 900 workers in London.
Fulfilling its work program through the end of the year “will be challenging,” the EMA said Friday, “particularly in view of the need to implement new legislation for veterinary medicines and medical devices.”
The regulator moved to the Netherlands earlier this year in anticipation of the U.K.'s departure from the European Union -- once envisioned to take place in March and now delayed until the end of October. Countries from across the bloc courted the EMA, offering employees perks such as housing discounts and access to schools for their children to help with staff retention.
Drugmakers wanting to get new products to market quickly have been watching the change warily, concerned about potential delays resulting from the drop in manpower. The EMA said it will integrate operations in human medicines to assure the quality of its scientific opinions.
“EMA's core activities to safeguard public and animal health and the medicines approval process have always been our priority,” Executive Director Guido Rasi said in an email. “We have had to take some difficult decisions on what activities to temporarily put on hold, but at no point have our core activities been compromised and this will not change.”
The regulator will review its organizational structure, while preparing task forces to focus on priorities such as digital business transformation, data analytics and methods, regulatory science and innovation, and clinical trials and manufacturing strategy, Rasi said in the statement.
“This will ensure that the agency is geared up for the future with more efficient processes firmly rooted in digital technology to keep pace with rapid advances in science,” the EMA said.
To contact the reporters on this story: John Lauerman in London at jlauerman@bloomberg.net;James Paton in London at jpaton4@bloomberg.net
To contact the editor responsible for this story: Eric Pfanner at epfanner1@bloomberg.net
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.